N-Acetylcysteine Increases Corneal Endothelial Cell Survival in a Mouse Model of Fuchs Endothelial Corneal Dystrophy

This laboratory and animal study investigated N-acetylcysteine as a potential treatment for Fuchs endothelial corneal dystrophy — a genetic disease of the eye’s inner corneal layer — using cell culture and a mouse model.

NAC enhanced corneal endothelial cell survival under oxidative and endoplasmic reticulum stress, and improved endothelial cell density and morphology in mutant mice. The mechanism involved upregulation of antioxidant pathways and reduction of ER stress markers.

This study is not related to cardiovascular disease. Fuchs corneal dystrophy is a distinct ophthalmic condition with no established connection to coronary artery disease or lipid metabolism. Its inclusion in this research library likely reflects a broad content harvest of NAC-related literature, given NAC’s proposed use as an antioxidant supplement across multiple disease areas.

The underlying science — NAC as a cellular antioxidant and ER stress modulator — is credible for its intended application. The leap to cardiovascular relevance requires an entirely separate body of evidence.

We rate the evidence limited in the context of cardiovascular disease research. The corneal findings are scientifically sound but not applicable to subclinical CAD diagnosis or prevention.